Walvax Biotechnology (300142.SZ) announced that on June 24, 2024, the company held its fifth Board of Directors meeting...
Watson Biotechnology (300142.SZ) announced that on June 24, 2024, the company held its 19th meeting of the fifth Board of Directors to deliberate and approve the motion on "Termination Agreement" regarding the termination of the technology development cooperation of novel coronavirus mRNA vaccines and herpes zoster mRNA vaccines with Suzhou Abogen Biosciences Co., Ltd. The Board agreed that the Company and its subsidiary, Yuxi Watson Biotechnology Co., Ltd. ("Yuxi Watson"), should terminate the technology development cooperation of novel coronavirus mRNA vaccines and herpes zoster mRNA vaccines with Suzhou Abogen Biosciences Co., Ltd. ("Abogen Biosciences"), and sign the Termination Agreement.